Table 2.
Inverse probability of treatment weighted patient characteristics by infarct location
| Patient characteristics | Inferior infarct | Non-inferior infarct | Sensitivity: anterior infarct | |||
|---|---|---|---|---|---|---|
| Catheter ablation (N = 63) | Escalated therapy (N = 72) | Catheter ablation (N = 69) | Escalated therapy (N = 55) | Catheter ablation (N = 46) | Escalated therapy (N = 37) | |
| Age (years)b | 68.4 ± 7.9 | 67.8 ± 8.0 | 66.1 ± 6.8 | 67.2 ± 7.3 | 64.6 ± 9.3 | 65.3 ± 9.1 |
| Women | 8% | 7% | 6% | 4% | 0.3% | 0.0% |
| Hypertension | 70% | 69% | 64% | 65% | 67% | 69% |
| Diabetes mellitus | 32% | 38%a | 24% | 22% | 15% | 14% |
| Coronary artery disease | 97% | 97% | 70% | 74% | 97% | 95% |
| Renal insufficiency | 20% | 18% | 17% | 19% | 12% | 12% |
| Atrial fibrillation/flutter | 38% | 42% | 42% | 52%a | 48% | 56%a |
| Prior stroke/TIA | 10% | 12% | 8% | 7% | 8% | 7% |
| SVT | 8% | 9% | 16% | 0%a | 15% | 13% |
| Torsades de pointes | 0% | 1% | 0% | 0% | 0% | 0% |
| Heart rate (b.p.m.)b | 63.5 ± 9.6 | 63.4 ± 10.1 | 63.2 ± 11.5 | 61.3 ± 11.4 | 63.4 ± 10.5 | 65.1 ± 10.9 |
| NYHA class | ||||||
| I | 28% | 24% | 16% | 16% | 28% | 30% |
| II | 55% | 58% | 53% | 51% | 14% | 16% |
| III | 17% | 18% | 31% | 33% | 58% | 54% |
| Location of infarctions | ||||||
| Inferior | 100% | 100% | 0% | 0% | 15% | 12% |
| Anterior | 14% | 18% | 46% | 48% | 100% | 100% |
| Septal | 13% | 13% | 18% | 17% | 10% | 7% |
| Posterolateral | 19% | 17% | 2% | 1% | 4% | 0%a |
| Apical | 17% | 18% | 6% | 5% | 12% | 12% |
| RV | 0% | 0% | 0% | 0% | 0% | 0% |
| Unknown | 0% | 0% | 0% | 0% | 0% | 0% |
| Other | 10% | 10% | 9% | 11% | 9% | 8% |
| ICD characteristics | ||||||
| ICD | ||||||
| Single chamber | 42% | 43% | 22% | 25% | 21% | 19% |
| Dual chamber | 44% | 44% | 48% | 44% | 42% | 40% |
| CRT-D | 14% | 13% | 30% | 31% | 37% | 41% |
| Mean number of shocks (3 months prior)b | 1.4 ± 1.2 | 1.6 ± 1.3 | 1.24 ± 3.3 | 0.71 ± 3.5a | 1.3 ± 2.9 | 1.2 ± 2.4 |
| Mean number ATP (3 months prior)b | 12.0 ± 29.4 | 13.3 ± 26.9 | 8.6 ± 19.5 | 9.0 ± 17.7 | 19.2 ± 26.9 | 13.5 ± 28.0a |
| Medications | ||||||
| AADsc | ||||||
| Amiodarone | 55% | 51% | 100% | 98% | 89% | 86% |
| <300 mg/day | 49% | 48% | 12% | 10% | 6% | 9% |
| ≥300 mg/day | 6% | 3% | 88% | 88% | 83% | 77% |
| Sotalol | 45% | 49% | 0% | 2% | 11% | 14% |
| Beta blockers | 63% | 62% | 96% | 96% | 97% | 97% |
| Digoxin | 22% | 26% | 18% | 15% | 24% | 23% |
AADs, antiarrhythmic drugs; ATP, antitachycardia pacing; CRT-D, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association; RV, right ventricle; SVT, supraventricular tachycardia; TIA, transient ischemic attack
a
SMD >10% are considered unbalanced. SMDs compared ablation patients to escalated therapy patients.
b
Presented as a mean (±standard deviation).
c
AADs taken within 4 weeks prior to randomization were included.